Paperless Validation to enable quicker patient-caregiver connection with minimal disruption to existing workflow.
SAN FRANCISCO, Dec. 19, 2018 /PRNewswire/
ValGenesis, Inc., a market leader in Enterprise Validation Lifecycle Management Solutions (VLMS), today announced that the world’s leading infusion therapy company has chosen ValGenesis’s 100% paperless Validation Lifecycle Management System to manage its validation lifecycle process across the organization.
This U.S.-based global company is a world leader in infusion therapy. For more than three decades, its singular focus has been on improving the safety and efficiency of IV therapy. Through a wide-ranging product portfolio that includes a full line of IV solutions, pumps, safety software, and consumables designed to be intuitive, easy to use, and interoperable, this company is helping clinicians reduce IV medication errors while streamlining the flow of data from pharmacy to bedside.
To expedite the patient-to-caregiver connection, the company decided to go paperless in their validation process after realizing traditional, manual, paper-based validation processes were proving both costly and inefficient. The company conducted a detailed evaluation process of multiple solutions and selected ValGenesis Enterprise VLMS—an electronic, paperless solution that well meets the organization’s validation lifecycle needs. With ValGenesis Enterprise VLMS, the company will significantly reduce validation cycle time, gain a higher standard of data integrity, improve its regulatory compliance process, and gain a holistic view of real-time validation status across its regulated systems, thereby improving the quality and speed of the entire process.
After the initial rollout of the ValGenesis solution, the company also plans to extend its use of the ValGenesis tool for their global commissioning and qualification needs.
“ValGenesis is excited on being selected by this global life science company to manage its validation lifecycle process, therein confirming the depth and width of functionality that our solution has to offer to meet their compliance, data integrity and good document practice needs,” says Narayan Raj, Vice President of ValGenesis Inc. “ValGenesis’ s continued investment in the research and development of the VLMS offering to meet industry validation and compliance needs, is paying dividends.”
Althea D’Sylva, ValGenesis Communications, +1 510-445-0505 Ex. 1026,
ValGenesis, Inc. is the creator of an innovative software platform that serves as the foundation for managing compliance-based validation activities in Life Science companies. ValGenesis, Inc. is the provider of the first enterprise application that manages the corporate validation lifecycle process. As the first fully paperless solution for 100 % electronic management of validation execution and approval, ValGenesis was selected by an industry peer review committee to receive the Parenteral Drug Association (PDA) New Innovative Technology Award in 2005. The solution is also fully compliant with U.S. FDA 21 CFR Part 11 and Annex 11 requirements.
For more information, visit https://www.valgenesis.com